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Abstract
Background: Cardiovascular disease (CVD), including coronary heart disease (CHD) and stroke, is the leading cause
of death and disability globally. A large proportion of mortality occurs in people with prior CHD and effective and
scalable strategies are needed to prevent associated deaths and hospitalisations. The aim of this study is to
determine if a practice-level collaborative quality improvement program, focused on patients with CHD, reduces
the rate of unplanned CVD hospitalisations and major adverse cardiovascular events, and increases the proportion
of patients achieving risk factor targets at 24 months.
Methods: Cluster randomised controlled trial (cRCT) to evaluate the effectiveness of a primary care quality
improvement program in 50 primary care practices (n~ 10,000 patients) with 24-month follow-up. Eligible practices
will be randomised (1:1) to participate in either the intervention (collaborative quality improvement program) or
control (standard care) regimens. Outcomes will be assessed based on randomised allocation, according to
intention-to-treat. The primary outcome is the proportion of patients with unplanned CVD hospitalisations at 2
years. Secondary outcomes are proportion of patients with major adverse cardiovascular events, proportion of
patients who received prescriptions for guideline-recommended medicines, proportion of patients achieving
national risk factor targets and proportion with a chronic disease management plan or review. Differences in the
proportion of patients who are hospitalised (as well as binary secondary outcomes) will be analysed using log-
binomial regression or robust Poisson regression, if necessary.
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Discussion: Despite extensive research with surrogate outcomes, to the authors’ knowledge, this is the first
randomised controlled trial to evaluate the effectiveness of a data-driven collaborative quality improvement
intervention on hospitalisations, CVD events and cardiovascular risk amongst patients with CHD in the primary care
setting. The use of data linkage for collection of outcomes will enable evaluation of this potentially efficient strategy
for improving management of risk and outcomes for people with heart disease.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR) number ACTRN12619001790134 (dated
20th December 2019).
Keywords: Quality improvement, Primary care, Secondary prevention, Coronary heart disease, Data, Cardiovascular
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Background
Cardiovascular disease (CVD), including coronary heart
disease (CHD) and stroke, is the leading cause of death
and disease burden globally [1]. CHD accounts for the
greatest single disease morbidity and nearly one fifth of
all deaths, with around a third of these occurring in
people who have prior CHD [2, 3]. With an aging popu-
lation, and more people surviving initial events, the bur-
den of CHD is increasing and is projected to rise from
around 47 million disability-adjusted life years (DALYs)
globally in 1990 to 82 million DALYs by 2020 [3].
However, despite international guidelines recommending
secondary prevention [4–6], adherence, access and sus-
tainability of their implementation is suboptimal. Use of
evidence-based secondary prevention medications and
lifestyle change both decline in the initial 6 months after
an event [7] and continue to decline thereafter [8].
Therefore, improving post-discharge care through sec-
ondary prevention strategies (healthy living, adherence
to medicines) is an international priority requiring in-
novative and efficient strategies that support better pa-
tient care [9, 10].
Collaborative quality improvement initiatives offer an
efficient way to support and improve health service de-
livery on a large scale. These ‘purposeful efforts to se-
cure positive change’ have become a focus of activity
within the international healthcare environment [11]. In
response to increasing health demand, the Institute for
Healthcare Improvement (US) developed the Break-
through Collaborative Quality Improvement Method-
ology to make rapid improvements in quality while
reducing costs [12]. This approach offers a scalable
model by targeting stakeholders to drive improvement,
leveraging the collective power of sites working simul-
taneously on the same problem and using data to drive
performance [12]. Collaborative methodology has been
applied to a range of healthcare systems with demon-
strated success in areas such as asthma [13], chronic
heart failure [14] and compliance with healthcare stan-
dards [15, 16]. While such programs have been evalu-
ated, evidence for their impact and effectiveness has only
focussed on surrogate endpoints and more robust evi-
dence is needed [17, 18].
In recent years, the expansion of technology has enabled
the integration of automated data extraction, which has
expanded opportunity for data-driven quality improve-
ment [19]. For example, in primary care, practices can
utilise their routinely collected data to inform practice-
level decision-making and implementation of associated
quality improvement [20]. As such, a focus on data-driven
quality improvement has become a key element within
contemporary literature outlining the building blocks of
high performing primary care practices [21]. Current data
shows that only 38% of Australian patients with CVD re-
ceive a government-funded chronic disease management
plan from their primary care provider [22]. The aim of the
QUEL (QUality improvement in primary care to prevent
hospitalisations and improve Effectiveness and efficiency
of care for people Living with CHD) study is to evaluate
whether a data-driven quality improvement program im-
plemented in primary care reduces CVD hospitalisations
and improves CVD risk factors and medication adherence
in patients with CHD over 24months.
Specific objectives are to determine if a primary care
practice-level, collaborative quality improvement program:
i. reduces the rate of unplanned CVD hospitalisations
and major adverse cardiovascular events (MACE) at
24 months in patients with CHD;
ii. increases the proportion of patients who are
prescribed evidence-based medications for CVD,
are achieving national targets for risk factors
(cholesterol, blood pressure (BP), smoking) and
have an active Chronic Disease Management
(CDM) or review plan in place and to;
iii. determine barriers and enablers associated with
implementation of the quality improvement program.
Methods/design
Study design
QUEL is a cluster randomised controlled trial (cRCT)
with 1:1 randomisation recruiting 50 Australian primary
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care practices (n~ 10,000 patients with CHD) with 24-
month follow-up to compare outcomes amongst prac-
tices allocated to collaborative quality improvement pro-
gram versus standard care (Fig. 1). Data will be collected
via linkage of routinely collected primary care practice
data with administrative data (hospitalisations, deaths
and pharmaceutical prescriptions).
Practices and patients
Primary care practices will be identified through Austra-
lian Primary Health Networks (PHNs) across two states
of Australia (New South Wales, Queensland). Research
team members and representatives from the Improve-
ment Foundation (an Australian not-for-profit organisa-
tion providing consultancy and training services in
quality improvement) will approach all PHNs in partici-
pating states and provide information about the study.
Supportive PHNs will then communicate with primary
care practices in their jurisdictions to seek expressions
of interest (EOI) for participating. Research team mem-
bers will coordinate receipt of EOIs and contact practice
staff to confirm eligibility and commence formal recruit-
ment processes, signing of agreements and enabling au-
tomated data extraction from practice software.
Inclusion and exclusion criteria for practice are detailed
below.
Practices will be eligible to participate if they;
i. manage ≥100 patients year with prevalent CHD and
ii. use practice software that is compliant with
Improvement Foundation systems (such as Medical
Director, Best Practice, Communicare, Monet and
Clarity which account for the majority of practice
management software market-share in Australia).
Practices will be excluded if:
i. they are unwilling to provide written agreement to
participate in the quality improvement program or
ii. the primary care practice is already participating in
a formal quality improvement project targeting
CVD.
The patient cohort for the QUEL will comprise a data-
set of all eligible patients presenting to participating
practices who meet the following inclusion criteria.:
i. are ≥18 years with a documented diagnosis of CHD
in the primary care record of a participating
practice, and
ii. have visited the participating practice at least once
in the previous 12 months.
Ethics
This study will adhere to the National Health and Med-
ical Research Council (NHMRC) ethical guidelines for
human research [23] and processes are detailed else-
where [24]. Given this is a cRCT with a practice-level
Fig. 1 Flow diagram of QUEL cRCT
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intervention, patient data will be extracted with a waiver
of consent. Ethics approval has been obtained from the
New South Wales Population & Health Services Re-
search Ethics Committee (HREC, HREC/18/CIPHS/44),
which also meets the formal approval requirements for
Queensland. A waiver of consent is required because it
will be impractical to collect individual consent from
each patient and data linkage will be via data extraction
from clinical software. The intervention will occur at the
practice-level and it is not anticipated there will be any
harm to individual patients. However, if a practice
wishes to withdraw from the study they will be free to
do so at any time. Any necessary protocol amendments
will be approved by the ethics committee, investigators,
trial registries and if required the journal should the
need arise.
Intervention and control groups
Practices allocated to the intervention will participate in a
CHD secondary prevention collaborative quality improve-
ment program. The program is designed to use data and
practice level engagement to implement rapid and progres-
sive changes based on Plan, Do, Study, Act (PDSA) cycles
for pre-determined performance targets [21]. The program
is underpinned by the psychology of behaviour change, ac-
tive practice-level engagement combined with extraction
and utilisation of electronically extracted data from practice
software [12]. Practices will collaborate and support each
other between and within practices in an ongoing way over
12months to achieve a set of key performance measures
(Table 1). These measures have been pre-determined based
on guidelines [6] and availability of data for extraction and
were developed and approved through an iterative process
involving study investigators, clinicians and quality im-
provement experts. Intervention practices will receive their
summarised performance data monthly.
The 12month intervention will deliver the collabora-
tive quality improvement program via (i) Learning work-
shops where a minimum of two practice staff (ideally
one GP and one practice staff) participate in two online
and two face-to-face learning workshops (based on
Langley and Nolan model for improvement) [21]; (ii) Ac-
tivity periods where practices use their own electronic-
ally extracted data to test and implement improvements
through cycles of small step-wise changes; (iii) Data
reporting and feedback where practices submit monthly
data and PDSA cycles on which they are provided ob-
jective feedback (telephone and in-person visits) on their
outcomes and progress and; (iv) Transfer where PHNs
share learnings from practices within their jurisdictions
[18]. Only personnel trained in delivery of collaborative
quality improvement will deliver the practice support
and all practices will have access to an online Sharepoint
website for regular communication and support.
Practices allocated to the control group will participate
in usual care without access to the quality improvement
intervention for CHD during the study period. Control
practices will be offered an opportunity to participate in
a series of virtual workshops after data collection has
closed. No individuals presenting to a participating prac-
tice (intervention or control) during the study period
will be restricted in any way in terms of the care and
treatment they receive from their healthcare providers.
As this is a cRCT, it is not anticipated any post-trial care
will be required for individual patients. However, after
completion of follow-up, practices allocated to the con-
trol group will be offered the opportunity to receive sup-
port for quality improvement activities via a virtual
program delivered by the Improvement Foundation.
Their participation will be voluntary and will not impact
on data collection.
Outcomes
The primary outcome is the proportion of patients with
unplanned CVD hospitalisations within 2 years of base-
line data extraction (and commencement of intervention
for those allocated to intervention group). For this study,
CVD is defined as any condition involving the heart,
brain or peripheral blood vessels and includes CHD
(such as angina and myocardial infarction, MI), cerebro-
vascular disease (such as stroke), peripheral arterial dis-
ease and other conditions including heart failure and
atrial fibrillation [25].
Table 1 QUEL intervention key performance measures
• Proportion of patients with CHD where LDL has been recorded within
the previous 12 months
• Proportion of patients with CHD whose most recent LDL result was
less than 2.0 mmol/L
• Proportion of patients with CHD with a recorded BP reading taken
within the previous 12 months
• Proportion of patients with CHD whose most recent BP reading, taken
within the previous 12 months, was less than or equal to 130/80
mmHg
• Proportion of patients with CHD whose smoking status has been
recorded
• Proportion of patients with CHD recorded as a current smoker
• Proportion of patients with CHD who are currently prescribed an anti-
platelet agent
• Proportion of patients with CHD who are currently prescribed a statin
• Proportion of patients with CHD who are currently prescribed an ACE
inhibitor or ARB
• The proportion of patients with CHD with MBS Items 721 or 732
claimed (GP Management Plans or review)
• Proportion of patients with CHD who have an influenza vaccination
recorded within the previous 12 months
CHD Coronary heart disease, LDL Low density lipoprotein, BP Blood pressure,
Angiotensin-converting-enzyme (ACE) inhibitor, ARB Angiotensin II receptor
blockers, MBS Medicare Benefits Scheme, GP General practice
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Secondary outcomes, also at 2 years) are;
i. Proportion of patients with major adverse cardiac
and cerebrovascular events (fatal and non-fatal) that
includes CHD (angina or MI), stroke or CVD
death,
ii. proportion of patients who received guideline-
recommended medicines,
iii. proportion of patients with a chronic disease
management plan or review (Australian Medicare
Item numbers 721 or 732 respectively) and;
iv. proportion of patients achieving national targets for
CVD risk factors (total cholesterol, systolic blood
pressure, smoking).
Data collection and management
All data will be collected at baseline, 12 and 24months.
CVD hospitalisations and cardiovascular events will be
collected via state-based administrative admissions data
(depending on location of recruited practices). Individual
patient deaths will be collected via linkage with the Na-
tional Death Index and medication prescriptions and
health service utilisation via linkage with the Australian
Government Department of Health Pharmaceutical Ben-
efits Scheme (PBS) and Medical Benefits Scheme (MBS)
schemes respectively. Probabilistic matching will be used
to link records and the estimated proportion of invalid
and missed links using data linkage will be very low [26].
Data collection pertaining to the proportion of patients
with chronic disease management plans and achieving
national risk factor targets (cholesterol, smoking, and
BP) will be electronically extracted from participating
practice software systems using an automated data ex-
traction tool with encrypted identifiers attached to pa-
tient data.
All data will be stored on a password-protected Secure
Unified Research Environment (SURE), which is a
purpose-built, remote-access data storage facility. This
environment allows researchers to safely access, store
and analyse study data [27]. Only aggregated and ana-
lysed data can be exported and data in SURE cannot be
copied, downloaded or transmitted by email or other
means. Only trained study research staff will have access
to the SURE facility through a staff-specific username
and password. The linked dataset will therefore be anon-
ymised and the research team who will be analysing the
data and delivering the intervention will not have access
to individual-level data. This maximises privacy and
forms an important aspect of the requirements for wai-
ver of consent approval. Electronic files containing
linked data for analysis will be stored on a Virtual Pro-
ject Workspace within SURE and the access period shall
be from study commencement for 7 years to enable all
analyses to be completed. At the end of this data
retention period, the tapes holding the archived data files
will be physically destroyed.
Randomisation
Practices will be randomised 1:1 to intervention (collab-
orative quality improvement program) or control groups
using a computer-generated sequence generated with
SAS 9.4 (Proc Surveyselect). Randomisation will be
stratified according to two subgroups - rural versus
urban location and size of the practice (≤2 versus > 2
GPs in a practice). The statistician performing random-
isation will be blinded to practice names and details and
only exposed to the practice characteristics that enable
stratification. Once allocation is completed, a research
team member will be provided the allocation list to en-
able communication with practices and commence ar-
rangements for their respective requirements. It is not
be possible to conceal the group allocation from the
practices themselves or the research team delivering the
intervention. However, given data is collected via linkage
and not performed by research staff, it is essentially con-
cealed. The statistician conducting analysis will be
blinded to practice allocation.
Sample size
The target sample size is 6050 (3025 per group), ob-
tained from 50 practices (25 per randomised group) with
an average cluster size of 121 patients per practice. This
is estimated to provide 80% power to detect a ratio of
the group proportions (or relative risk) of 0.75. This
sample size assumes a control group readmission rate of
35% based on a recent Australian cohort study (n =
6172) reporting an atherothrombotic disease readmis-
sion rate of 35% at 2 years for patients with CHD [28].
The estimation assumes a significance level of 0.05 and
an intra-class correlation coefficient (ICC) of 0.05. The
ICC is based on data from two cross-sectional studies in
Australian primary care [29, 30]. Loss to follow-up is an-
ticipated to be very minimal given the primary outcome
will be obtained via data linkage [26].
Statistical analyses
Analyses will be conducted at the individual level while
accounting for clustering of patients within practices.
Intention-to-treat principle will be followed with pa-
tients analysed according to their randomisation group.
Differences in the proportion of patients who are hospi-
talised (as well as binary secondary outcomes) will be
analysed using log-binomial regression or robust Poisson
regression in case of convergence issues. Clustering will
be accounted for by modelling the correlation among
patients from the same cluster using generalised estimat-
ing equations with an exchangeable correlation struc-
ture. Sensitivity analyses will include analyses of yearly
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rates using Poisson regression and/or time-to-event ana-
lyses via Cox models. Adjusted analyses will also be per-
formed to account for baseline imbalances in cluster and
patient characteristics. Pre-specified sub-group analyses
will be used to determine the impact of the intervention
on different patient groups (male v female; low SES v high
SES, different CVD subgroups, influenza vaccination or
not) and practice types (e.g., large v small and urban v
rural). This will be done by adding the subgroup variable
as well as its interaction with the intervention to the main
analysis model. As data will be extracted from primary
care practice clinical records and administrative data, if
not recorded, it will be assumed that the task has not been
done. A detailed analysis plan including mock tables will
be developed and signed-off prior to unblinding.
Barriers and enablers to implementation
This evaluation will enable examination of barriers and
enablers to implementation of the quality improvement
program. For example, level of support and expertise
needed for practices to engage with the intervention as
well as time spent preparing PDSA cycles and their de-
livery. Analyses will be informed by the Pawson and Til-
ley realistic evaluation model, which seeks to understand
human choices and actions, within a systems context
[31]. We will use a mixed methods approach with 3 data
sources: (i) quantitative data related to practice engage-
ment, attendance, time commitment, software capability,
staff skills and capacity; (ii) survey of intervention prac-
tices to examine satisfaction and utility and (iii) semi-
structured interviews with practice staff who participated
in workshops and PHN representatives to identify cap-
ability and barriers and enablers to implementation. To
obtain a broad range of views we will use maximum
variation purposive sampling based on patient and prac-
tice characteristics [32]. Sampling will continue until
thematic saturation is reached. Analyses (NVivo 11) will
be thematic with coding based on emergent themes.
Discussion
To the authors’ knowledge this is the first randomised
controlled trial to evaluate the effectiveness of a data-
driven collaborative quality improvement intervention in
primary care on hospitalisations and events amongst pa-
tients with CHD. The use of data linkage for collection
of outcomes will enable evaluation of this potentially ef-
ficient strategy for improving management of risk and
outcomes for people with CHD. Dissemination plans at
the conclusion of the study include a written report to
all investigators, PHNs and practices involved in the
study. In addition, the results will be submitted to a peer
reviewed journal and presented at scientific conferences.
Evidence from a recent systematic review (64 studies)
found that collaborative quality improvement promotes
shared learning and clinical processes [33]. However, the
authors conclude by highlighting that although results
are encouraging the studies lack scientific quality and ro-
bust methodology. The QUEL study will overcome these
limitations and the design has enabled collection of data
for hospitalisations for a large population.
At the conclusion of this trial we expect to have evi-
dence for a scalable solution to the evidence-practice
gaps in secondary prevention of CHD. We will have de-
termined the impact of the intervention on health out-
comes (hospitalisations, proportion of patients with
management plans and risk factor levels). We will also
have rigorous data about program implementation in
terms of barriers and enablers and we will have the first
high-quality evidence in the world on the effectiveness
and of implementing a collaborative quality improve-
ment strategy. We will therefore be in a strong position
to inform policy and to create an implementation plan.
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